GlassScriptPhysician profile
Harjeet Narula
NPI 1811928799
$19,814.25
in general payments reported to CMS, 2019-2025
71 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,207 · 2020: $3,050 · 2021: $3,016 · 2022: $2,482 · 2023: $3,238 · 2024: $2,573 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,033 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,033.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,191.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,930.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,471.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $1,442.16 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $818.74 | 2019-2024 | Fanapt, Hetlioz |
| Abbvie INC. | $798.59 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $660.47 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.39 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Corcept Therapeutics | $622.64 | 2021-2025 | Korlym |
| Cequr Corporation | $473.72 | 2024-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $457.09 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $453.74 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $443.01 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $380.91 | 2021-2025 | Caplyta |
| Allergan, INC. | $367.01 | 2019-2020 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harjeet Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.